REGULATION OF COMPASSIONATE USE PROGRAMS FOR EXPERIMENTAL BIOTECH DRUGS IN JAPAN

INTRODUCTION

Compassionate use refers to providing investigational medicines to patients suffering from serious or life-threatening diseases who cannot obtain adequate treatment through approved therapies or ordinary clinical trials. In biotechnology, this may involve experimental gene therapies, cell-based medicines, monoclonal antibodies, recombinant proteins and advanced biological products.

Japan introduced its compassionate-use framework in 2016 through the system of Expanded Access Trials (拡大治験). Its purpose is to provide access to promising investigational products while maintaining patient safety, ethical supervision and the integrity of ongoing clinical development.

The principal regulatory framework includes the Pharmaceuticals and Medical Devices Act (PMD Act), Good Clinical Practice (GCP) regulations, MHLW administrative notifications and the Patient-Proposed Healthcare Services System.

1. LEGAL AND REGULATORY FRAMEWORK

The principal legal instruments include:

PMD Act 1960: Regulates pharmaceutical approval, clinical investigations, manufacturing and marketing.

GCP Ministerial Ordinance: Establishes requirements for clinical trial conduct, informed consent, monitoring and investigational product management.

MHLW Notification No. 0122-7 of 22 January 2016: Established the Japanese compassionate-use framework for investigational drugs.

Clinical Trials Act 2017: Governs specified clinical research and associated ethical and scientific oversight.

Act on the Safety of Regenerative Medicine: Provides additional oversight for relevant cell-based and regenerative medical interventions.

The PMDA provides regulatory information, clinical trial guidance and access to information concerning expanded access trials.

2. ELIGIBILITY FOR COMPASSIONATE USE

Expanded Access Trials generally concern patients satisfying the following conditions:

The patient suffers from a serious or life-threatening disease.

Existing treatment options do not provide effective therapeutic alternatives.

The investigational product has reached an advanced stage of domestic clinical development.

The patient cannot participate in the principal clinical trial.

There is a reasonable scientific basis for anticipating potential therapeutic benefit.

The framework principally concerns investigational products from a pivotal domestic clinical trial after recruitment has ended or following completion of that trial.

Experimental medicines are not automatically eligible merely because a patient has exhausted conventional treatments.

3. APPLICATION AND APPROVAL PROCEDURE

The compassionate-use process generally involves the following stages:

A. Patient request: The patient discusses potential access with the treating physician.

B. Physician assessment: The physician evaluates the patient's medical condition, previous treatments and suitability for investigational treatment.

C. Sponsor consultation: The treating physician requests consideration from the clinical trial sponsor or investigator.

D. Regulatory coordination: The competent authorities may request the sponsor to consider implementing an expanded access trial.

E. Ethical review: The applicable institutional review board or other competent ethics committee evaluates the research protocol.

F. Clinical implementation: If the necessary regulatory and ethical requirements are satisfied, treatment proceeds under the clinical trial framework.

The sponsor retains discretion over whether to provide the investigational product. Expanded access is not a general legal obligation imposed on pharmaceutical companies.

4. REGULATION OF BIOTECHNOLOGY DRUGS

Special considerations apply to experimental biotechnology medicines.

Gene therapy: Requires assessment of genetic modification risks, long-term safety and potential unintended biological effects.

Cell-based medicines: Require appropriate controls over cell sourcing, manufacturing consistency, contamination and biological activity.

Monoclonal antibodies: Require evaluation of immunogenicity, infusion reactions and other clinically significant adverse effects.

Recombinant biological products: Require validated manufacturing procedures, product characterization and stability controls.

Personalized biological therapies: Require appropriate patient-selection criteria and reliable clinical monitoring.

Products involving regenerative medicine may also fall within the additional requirements of the Act on the Safety of Regenerative Medicine.

5. INFORMED CONSENT AND ETHICAL SAFEGUARDS

Patients must receive adequate information about the experimental nature of treatment.

Important disclosures include:

The investigational status of the drug.

Available conventional treatment alternatives.

Known and potential adverse effects.

Scientific uncertainties.

Expected therapeutic benefits.

Treatment costs and financial responsibilities.

Data collection and confidentiality.

The right to withdraw consent.

Consent must be voluntary and appropriately documented.

Particular safeguards are necessary for children, patients lacking decision-making capacity and other vulnerable populations.

6. COSTS AND FINANCIAL RESPONSIBILITY

Compassionate-use treatment is not automatically free in Japan.

Depending on the applicable trial arrangements, the sponsor may provide the investigational product without charge, while patients may remain responsible for certain medical expenses.

Under the separate Patient-Proposed Healthcare Services System, unapproved treatment costs are generally borne by the patient, while eligible insured medical services may receive public insurance coverage.

This system does not authorize unrestricted mixing of insured and uninsured medical services.

7. SAFETY MONITORING AND POST-TREATMENT OBLIGATIONS

Manufacturers and investigators must maintain appropriate safety-monitoring arrangements.

These include:

Recording adverse events.

Reporting serious adverse events under applicable GCP requirements.

Monitoring treatment effectiveness.

Maintaining investigational product traceability.

Reporting relevant safety information.

Protecting patient medical information.

Implementing corrective actions where necessary.

Suspending or discontinuing treatment when required for patient protection.

The sponsor must also ensure that compassionate-use activities do not adversely affect the principal clinical development programme.

8. CASE LAWS AND JUDICIAL AUTHORITIES

There is no established Japanese Supreme Court judgment specifically deciding a patient's legal entitlement to compassionate access to experimental biotechnology drugs. The following decisions provide analogous legal principles.

1. Jehovah's Witness Blood Transfusion Case – Supreme Court, 29 February 2000

The Court recognized the importance of patient autonomy and informed consent in medical treatment.

Relevance: Patients considering experimental biotechnology medicines must receive meaningful information before consenting.

2. Alternative Treatment Disclosure Case – Supreme Court, 27 November 2001

The Court examined the physician's duty to explain relevant alternative treatment options.

Relevance: Doctors discussing compassionate-use medicines should explain available conventional and investigational alternatives.

3. Cancer Diagnosis Disclosure Case – Supreme Court, 1995

The Court considered medical disclosure obligations in circumstances involving a serious cancer diagnosis.

Relevance: The judgment provides analogous guidance concerning sensitive medical information and communication with patients seeking experimental treatment.

4. Iressa Product Liability Litigation – Tokyo District Court, 23 March 2011

The Court considered pharmaceutical manufacturer responsibility concerning warnings about serious adverse effects.

Relevance: Experimental biotechnology drug providers must communicate material risks and maintain appropriate safety information. The judgment was subsequently overturned.

5. Iressa Product Liability Litigation – Osaka District Court, 25 February 2011

The Court considered product defects, pharmaceutical warnings and manufacturer liability.

Relevance: Compassionate-use sponsors should maintain appropriate product-safety documentation and communicate known risks. The relevant judgment was subsequently overturned.

6. Iressa Litigation – Supreme Court, 12 April 2013

The Supreme Court rejected the plaintiffs' appeal in the litigation concerning alleged pharmaceutical defects and inadequate warnings.

Relevance: The case illustrates the importance of evaluating pharmaceutical safety and manufacturer responsibility against the applicable scientific knowledge.

These decisions are analogous authorities rather than direct precedents governing Japanese compassionate-use applications.

9. PRACTICAL COMPLIANCE REQUIREMENTS

Biotechnology companies intending to operate compassionate-use programmes in Japan should:

Determine whether the investigational product qualifies for expanded access.

Establish communication procedures with treating physicians.

Maintain appropriate clinical trial authorization and notifications.

Obtain applicable ethics committee review.

Implement informed-consent documentation.

Maintain GCP-compliant manufacturing and product controls.

Establish adverse-event reporting systems.

Protect confidential patient and genetic information.

Document decisions concerning acceptance or refusal of requests.

Maintain long-term safety-monitoring arrangements where required.

CONCLUSION

Japan regulates compassionate use of experimental biotechnology medicines primarily through the Expanded Access Trials framework established in 2016. The system seeks to balance urgent patient needs against scientific uncertainty, pharmaceutical safety and the integrity of clinical development.

The PMD Act, GCP regulations, MHLW notifications and Patient-Proposed Healthcare Services System provide complementary regulatory mechanisms.

Although direct judicial precedents concerning compassionate-use biotechnology drugs remain limited, Japanese decisions on informed consent, alternative treatment disclosure and pharmaceutical product liability provide important analogous principles.

Ultimately, Japan's regulatory approach allows carefully controlled access to promising experimental treatments without treating compassionate use as an automatic entitlement or a substitute for formal pharmaceutical approval.